{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:19Z","timestamp":1786979899331,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C18928\/A8548"],"award-info":[{"award-number":["C18928\/A8548"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The North West London Hospitals NHS Trust"},{"name":"The Northwick Park Hospital Leukemia Research Trust Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00262-020-02725-2","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T13:05:06Z","timestamp":1602162306000},"page":"1127-1142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm"],"prefix":"10.1007","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8972-5697","authenticated-orcid":false,"given":"Nicki","family":"Panoskaltsis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil E.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Stagg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J.","family":"Mummery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariwan","family":"Husni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naila","family":"Arebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Greenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire L.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafid O.","family":"Al-Hassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michalis","family":"Koutinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Mantalaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella C.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,8]]},"reference":[{"issue":"5","key":"2725_CR1","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nm.4321","volume":"23","author":"CH June","year":"2017","unstructured":"June CH, Warshauer JT, Bluestone JA (2017) Is autoimmunity the Achilles\u2019 heel of cancer immunotherapy? Nat Med 23(5):540\u2013547","journal-title":"Nat Med"},{"issue":"1","key":"2725_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM (2018) CTLA-4: a moving target in immunotherapy. Blood 131(1):58\u201367","journal-title":"Blood"},{"key":"2725_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2018.10.017","volume":"107","author":"Y Kanjanapan","year":"2019","unstructured":"Kanjanapan Y, Day D, Butler MO et al (2019) Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials. Eur J Cancer 107:1\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2018.10.017","journal-title":"Eur J Cancer"},{"key":"2725_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"issue":"18","key":"2725_CR5","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-15-2569","volume":"22","author":"S Cousin","year":"2016","unstructured":"Cousin S, Italiano A (2016) Molecular pathways: immune checkpoint antibodies and their toxicities. Clin Cancer Res 22(18):4550\u20134555","journal-title":"Clin Cancer Res"},{"key":"2725_CR6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:188\u2013195","journal-title":"Blood"},{"issue":"6","key":"2725_CR7","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey DT, Lacey SF, Shaw PA et al (2016) Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 6(6):664\u2013679","journal-title":"Cancer Discov"},{"key":"2725_CR8","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D et al (2018) Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov 8:958\u2013971","journal-title":"Cancer Discov"},{"key":"2725_CR9","doi-asserted-by":"publisher","first-page":"e529","DOI":"10.1016\/S1470-2045(16)30571-X","volume":"16","author":"W Wick","year":"2016","unstructured":"Wick W, Hertenstein A, Platten M (2016) Neurological sequelae of cancer immunotherapies and targeted therapies. Lancet Oncol 16:e529\u2013e541. https:\/\/doi.org\/10.1016\/S1470-2045(16)30571-X","journal-title":"Lancet Oncol"},{"key":"2725_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M et al (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73:1\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.001","journal-title":"Eur J Cancer"},{"issue":"12","key":"2725_CR11","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi L-A et al (2017) Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 7(12):1404\u20131419. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0698","journal-title":"Cancer Discov"},{"key":"2725_CR12","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, van der Stegen SJC, Eyquem J et al (2018) CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med 24:731\u2013738","journal-title":"Nat Med"},{"issue":"6","key":"2725_CR13","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G et al (2018) Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 24(6):739\u2013748. https:\/\/doi.org\/10.1038\/s41591-018-0036-4","journal-title":"Nat Med"},{"key":"2725_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aax7969","author":"Y Liu","year":"2020","unstructured":"Liu Y, Fang Y, Chen X et al (2020) Gasdermin E\u2013mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.aax7969","journal-title":"Sci Immunol"},{"key":"2725_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-018-0774-y","volume":"564","author":"V Staedtke","year":"2018","unstructured":"Staedtke V, Bai R, Kim K et al (2018) Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature 564:273\u2013277. https:\/\/doi.org\/10.1038\/s41586-018-0774-y","journal-title":"Nature"},{"key":"2725_CR16","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0473","author":"S Agarwal","year":"2020","unstructured":"Agarwal S, June CH (2020) Harnessing CAR T cell insights to develop treatments for hyperinflammatory responses in COVID-19 patients. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0473","journal-title":"Cancer Discov"},{"issue":"21","key":"2725_CR17","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi L-A, Li D et al (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy. Blood 130(21):2295\u20132306","journal-title":"Blood"},{"key":"2725_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0602-4","author":"RL Chua","year":"2020","unstructured":"Chua RL, Lukassen S, Trump S et al (2020) COVID-19 severity correlates with airway epithelium-immune cell interaction identified by single-cell analysis. Nat Biotechnol. https:\/\/doi.org\/10.1038\/s41587-020-0602-4","journal-title":"Nat Biotechnol"},{"key":"2725_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd7114","author":"L Kuri-Cervantes","year":"2020","unstructured":"Kuri-Cervantes L, Pampena MB, Meng W et al (2020) Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.abd7114","journal-title":"Sci Immunol"},{"issue":"42","key":"2725_CR20","doi-asserted-by":"publisher","first-page":"11919","DOI":"10.1073\/pnas.1611421113","volume":"113","author":"SK Subudhi","year":"2016","unstructured":"Subudhi SK, Aparicio A, Gao J et al (2016) Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Nat Acad Sci 113(42):11919\u201311924","journal-title":"Proc Nat Acad Sci"},{"issue":"3","key":"2725_CR21","doi-asserted-by":"publisher","first-page":"P819","DOI":"10.1016\/j.celrep.2019.06.049","volume":"28","author":"FJ Hartmann","year":"2019","unstructured":"Hartmann FJ, Babdor J, Gherardini PF et al (2019) Comprehensive immune monitoring of clinical trials to advance human immunotherapy. Cell Reports 28(3):P819\u2013831.e4","journal-title":"Cell Reports"},{"issue":"6","key":"2725_CR22","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1158\/0008-5472.CAN-16-2324","volume":"77","author":"DY Oh","year":"2017","unstructured":"Oh DY, Cham J, Zhang L et al (2017) Immune toxicities elicited by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire. Cancer Res 77(6):1322\u20131330","journal-title":"Cancer Res"},{"issue":"8","key":"2725_CR23","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","volume":"22","author":"PS Hegde","year":"2016","unstructured":"Hegde PS, Karanikas V, Evers S (2016) The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res 22(8):1865\u20131874. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1507","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2725_CR24","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1053\/j.seminoncol.2015.02.016","volume":"42","author":"B Weide","year":"2015","unstructured":"Weide B, Di Giacomo AM, Fonsatti E, Zitvogel L (2015) Immunologic correlates in the course of treatment with immunomodulating antibodies. Semin Oncol 42(3):448\u2013458. https:\/\/doi.org\/10.1053\/j.seminoncol.2015.02.016","journal-title":"Semin Oncol"},{"issue":"5","key":"2725_CR25","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-18-2795","volume":"25","author":"SY Lim","year":"2019","unstructured":"Lim SY, Lee JH, Gide TN et al (2019) Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy. Clin Cancer Res 25(5):1557\u20131563. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2795","journal-title":"Clin Cancer Res"},{"key":"2725_CR26","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa063842","volume":"355","author":"G Suntharalingam","year":"2006","unstructured":"Suntharalingam G, Perry M, Ward S et al (2006) Cytokine Storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018\u20131028","journal-title":"N Engl J Med"},{"issue":"3","key":"2725_CR27","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1084\/jem.20051060","volume":"202","author":"N Beyersdorf","year":"2005","unstructured":"Beyersdorf N, Gaupp S, Balbach K et al (2005) Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med 202(3):445\u2013455","journal-title":"J Exp Med"},{"key":"2725_CR28","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/sj.leu.2402835","volume":"17","author":"N Panoskaltsis","year":"2003","unstructured":"Panoskaltsis N, Reid CDL, Knight SC (2003) Quantification and cytokine production of circulating lymphoid and myeloid cells in acute myelogenous leukemia (AML). Leukemia 17:716\u2013730","journal-title":"Leukemia"},{"key":"2725_CR29","doi-asserted-by":"publisher","DOI":"10.4324\/9781410609243","volume-title":"Designing experiments and analysing data: a model comparison perspective","author":"S Maxwell","year":"2003","unstructured":"Maxwell S, Delaney H (2003) Designing experiments and analysing data: a model comparison perspective. Lawrence Erlbaum Associates, New Jersey"},{"key":"2725_CR30","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.neurobiolaging.2004.05.010","volume":"26","author":"R Mrak","year":"2005","unstructured":"Mrak R, Griffin W (2005) Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 26:349\u2013354","journal-title":"Neurobiol Aging"},{"issue":"10","key":"2725_CR31","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.it.2008.07.007","volume":"29","author":"J Kipnis","year":"2008","unstructured":"Kipnis J, Derecki N, Yang C, Scrable H (2008) Immunity and cognition: what do age-related dementia, HIV-dementia and \"chemo-brain\" have in common? Trends Immunol 29(10):455\u2013463","journal-title":"Trends Immunol"},{"key":"2725_CR32","unstructured":"TGN1412 Investigator's Brochure. TeGenero Immunotherapeutics. (Accessed 5 May, 2006, at https:\/\/www.mhra.gov.uk\/home\/idcplg?IdcService=GET_FILE&dDocName=CON2023518&RevisionSelectionMethod=LatestReleased.)"},{"issue":"21","key":"2725_CR33","doi-asserted-by":"publisher","first-page":"8180","DOI":"10.1073\/pnas.0402268101","volume":"101","author":"J Kipnis","year":"2004","unstructured":"Kipnis J, Cohen H, Cardon M, Ziv Y, Schwartz M (2004) T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. Proc Natl Acad Sci USA 101(21):8180\u20138185","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"2725_CR34","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","volume":"24","author":"K Beck","year":"2006","unstructured":"Beck K, Blansfield J, Tran K et al (2006) Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24(15):2283\u20132289","journal-title":"J Clin Oncol"},{"issue":"6","key":"2725_CR35","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/ni.1613","volume":"9","author":"E Volpe","year":"2008","unstructured":"Volpe E, Sevant N, Zollinger R et al (2008) A critical function for transforming growth factor-\u03b2, interleukin 23 and proinflammatory cytokines in driving and modulating human TH-17 responses. Nat Immunol 9(6):650\u2013657","journal-title":"Nat Immunol"},{"key":"2725_CR36","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.4049\/jimmunol.181.3.1908","volume":"181","author":"G Stummvoll","year":"2008","unstructured":"Stummvoll G, DiPaolo R, Huter E et al (2008) Th1, Th2, and Th17 effector T cell-induced autoimmune gastitis differs in pathological pattern and in susceptibility to suppression by regulatory T cells. J Immunol 181:1908\u20131916","journal-title":"J Immunol"},{"key":"2725_CR37","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jss.2008.10.003","volume":"155","author":"Y Shang","year":"2009","unstructured":"Shang Y, Li X, Prasad P et al (2009) Erythropoietin attenuates lung injury in lipopolysaccharide treated rats. J Surgical Res 155:104\u2013110","journal-title":"J Surgical Res"},{"issue":"4","key":"2725_CR38","doi-asserted-by":"publisher","first-page":"e1924","DOI":"10.1371\/journal.pone.0001924","volume":"3","author":"R Yuan","year":"2008","unstructured":"Yuan R, Maeda Y, Li W et al (2008) Erythropoietin: a potent induces of peripheral immuno\/inflammatory modulation in autoimmune EAE. PLoS ONE 3(4):e1924","journal-title":"PLoS ONE"},{"issue":"10","key":"2725_CR39","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1182\/blood.V89.10.3700","volume":"89","author":"C Mackall","year":"1997","unstructured":"Mackall C, Fleisher T, Brown M et al (1997) Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 89(10):3700\u20133707","journal-title":"Blood"},{"issue":"3","key":"2725_CR40","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1056\/NEJM199501193320303","volume":"332","author":"C Mackall","year":"1995","unstructured":"Mackall C, Fleisher T, Brown M et al (1995) Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 332(3):143\u2013149","journal-title":"N Engl J Med"},{"key":"2725_CR41","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nri778","volume":"2","author":"S Kaech","year":"2002","unstructured":"Kaech S, Wherry E, Ahmed R (2002) Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2:251\u2013262","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"2725_CR42","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/90950","volume":"7","author":"D Homann","year":"2001","unstructured":"Homann D, Teyton L, Oldstone M (2001) Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory. Nat Med 7(8):913\u2013919","journal-title":"Nat Med"},{"key":"2725_CR43","doi-asserted-by":"publisher","first-page":"212","DOI":"10.4049\/jimmunol.167.1.212","volume":"167","author":"J Faint","year":"2001","unstructured":"Faint J, Annels N, Curnow S et al (2001) Memory T cells constitute a subset of the human CD8+CD45RA+ pool with distinct phenotypic and migratory characteristics. J Immunol 167:212\u2013220","journal-title":"J Immunol"},{"key":"2725_CR44","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1172\/JCI113333","volume":"81","author":"F Levi","year":"1988","unstructured":"Levi F, Canon C, Touitou Y et al (1988) Seasonal modulation of the circadian time structure of circulating T and natural killer lymphocyte subsets from healthy subjects. J Clin Invest 81:407\u2013413","journal-title":"J Clin Invest"},{"key":"2725_CR45","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1749-6632.1991.tb27251.x","volume":"618","author":"F Levi","year":"1991","unstructured":"Levi F, Canon C, Dipalma M et al (1991) When should the immune clock be reset? From circadian pharmacodynamics to temporally optimized drug delivery. Ann N Y Acad Sci 618:312\u2013329","journal-title":"Ann N Y Acad Sci"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02725-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02725-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02725-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:15:41Z","timestamp":1744164941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02725-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,8]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["2725"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02725-2","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,8]]},"assertion":[{"value":"5 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None of the authors declare a financial conflict of interest. NP, SCK, MH, DG, CLP, HOA, MK, and AM declare no conflicts of interest. NEM is supported by a Career Development Award from The Medical Research Council (Grant Ref: MR\/R008302\/1) and is in receipt of a project grant from Bart\u2019s and The London Charity (MGU0465). He has also received consultancy fees and funding for research from ImCheck Therapeutics SAS. AJS research is supported by grants from Gilead Sciences AbbVie, The Medical College of St Bartholomew's Hospital Trust, Bowel & Cancer Research and Bart's Charity. CLM has received consultancy fees from Roche and Biogen for clinical trials in Alzheimer's disease, not relevant to the work presented here. NA has received honoraria from Janssen and Pfizer and also consulting for Janssen. She also has an affiliation with Imperial College London. SCK, NEM and AJS have done contract work for Parexel pre-dating the work described in this report. At the time of this work and report, Parexel Clinical Trials Unit had a short-term contract with the Antigen Presentation Research Group (APRG) to use a Class II cabinet within the laboratory. The APRG has also been contracted to perform immunological studies by a pharmaceutical company, the tissue specimens for which were supplied on behalf of that company via Parexel which is located adjacent to the APRG department. There is no conflict of interest involved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Ethics approval had been obtained for the TGN1412 trial (by the investigators\u2014none of the authors of this report were involved in the clinical trial). At the time of the trial-related serious adverse event, clinical and immune monitoring ensued as a matter of standard clinical care; no studies were done outside what was required for clinical care of the patients. Discussions between the Ethics Committee, MHRA and Expert Scientific Group set-up by the Minister of Health (UK) at the time in order to investigate the trial outcome unanimously concluded that the monitoring (as outlined in this report) should continue for standard of care, and that specific ethics approval was not required due to the extraordinary circumstances.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patients consented to clinical follow-up and immune monitoring. None of the authors of this work were involved with the conduct of the clinical trial or any of the pre-clinical testing of TGN1412. The patient cohort had consented to the TGN1412 first-in-man clinical trial that resulted in the cytokine storm serious adverse event. At the time of the start of sample collection for the current report, the patients had been removed from the trial and were being treated based on clinical need, rather than trial protocol.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Patients have provided written informed consent to the publication of the clinical follow-up and immune monitoring data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}